ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0241

RBT-1 Safety and Cytoprotective Response Biomarkers in Healthy Volunteers and Subjects with CKD

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Singh, Bhupinder, University of California Irvine, Irvine, California, United States
  • Goldstein, Stuart, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
  • Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
  • Zager, Richard A., University of Washington, Seattle, Washington, United States
Background

RBT-1 (stannous protoporphyrin [SnPP] with iron sucrose [FeS]) is a novel drug designed to precondition organs to prevent acute injury via activation of Nrf2, anti-inflammatory, and iron sequestering pathways. Pretreatment with RBT-1 in several animal models of acute kidney injury (AKI) has demonstrated protection from AKI in conjunction with upregulation of cytoprotective proteins. Here, we report results of a Phase 1b study of RBT-1 that assessed safety and cytoprotective response biomarker induction in healthy volunteers and subjects with stage 3 and 4 chronic kidney disease (CKD).

Methods

Fifty-four (54) subjects (18 healthy volunteers and 36 subjects with CKD) were enrolled and received a single IV dose of RBT-1 (9, 27, 45, 63, or 90 mg SnPP with 240 mg FeS). Plasma heme oxygenase-1 (HO-1), interleukin-10 (IL-10) and ferritin were selected as surrogate measures of organ protective activity. Safety was assessed through Day 29, and cytoprotective response biomarkers were assessed through 168 hours post-dose.

Results

RBT-1 was well tolerated in both healthy volunteers and subjects with CKD. The most common treatment-emergent adverse event was photosensitivity reaction (a known reaction to SnPP), which occurred in 15 subjects (27.8%) and was more commonly observed in the higher dose groups (63 and 90 mg SnPP/240 mg FeS). Photosensitivity was transient and generally mild in intensity. No serious adverse events were reported. RBT-1 induced dose-dependent, statistically significant increases in cytoprotective response biomarkers in both healthy volunteers and subjects with CKD. Peak increases from baseline in healthy volunteers and subjects with CKD were: 386% and 402% for HO-1, respectively; 99% and 332% for IL-10, respectively; and 1552% and 469% for ferritin, respectively.

Conclusion

RBT-1 is well tolerated with a similar safety profile in healthy volunteers and subjects with CKD Stage 3 or 4 and elicits a biomarker response in humans that is associated with RBT-1-mediated organ protection in animal models of AKI. The positive safety and biomarker efficacy data provide a strong scientific basis to study RBT-1 as an AKI prevention strategy in patients undergoing elective cardiac surgery.

Funding

  • Commercial Support